Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma

Miramar, Florida, April 30, 2012 - BUSINESS WIRE-- Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics for curative treatment of metastatic malignancies, announced today that it will jointly sponsor with the Melanoma Research Alliance (MRA) a clinical study of Altor’s novel IL-15 superagonist, ALT-803, against metastatic melanoma at the University of Washington. MRA is a public charity focused on funding the most promising melanoma research worldwide.

MRA selected the project led by Dr. Kim Margolin at the University of Washington in collaboration with Altor for funding under its Academic-Industry Partnership grant program. MRA’s grant, in conjunction with Altor’s support, will allow Dr. Margolin to conduct a first-in-human safety and efficacy clinical trial of ALT-803 in patients with incurable melanoma. The project will also include research studies on the effects of ALT-803 on the immune system to better understand how it works against melanoma. The results from this trial will further guide Altor’s development of ALT-803 against other metastatic malignancies and viral infections.

Hing Wong, Ph.D., Altor's CEO commented, "We are very pleased that MRA recognizes the potential of ALT-803 as a curative treatment for melanoma. Altor’s IL-15 technology programs have also received funding in the form of two Small Business Innovation Research grants from the National Cancer Institute and a James & Esther King Biomedical Research Grant, awarded by Florida’s Department of Health, to Altor’s collaborators at the MD Anderson Cancer Center, Orlando. We are thrilled by the wide recognition our IL-15 therapeutic approaches have received from these prestigious research institutes and foundations.”

About Altor’s IL-15 Technology

IL-15 is a critical factor for the development, proliferation and activation of cellular immune responses and is considered one of the most promising cancer immunotherapeutic agents. ALT-803 is a novel and proprietary IL-15 superagonist complex developed by Altor and will be in clinical development for patients with solid and hematological tumors later this year.

About Altor BioScience

Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary technology platforms. Altor currently has two products, ALT-801 and ALT-836, in six Phase II trials for cancer and life-threatening inflammatory disease indications.

Visit www.altorbioscience.com for details.

Contact: Altor Bioscience Corporation, Peter Rhode, Ph.D., 954-443-8600